Sutro Biopharma, Inc. (STRO): Price and Financial Metrics


Sutro Biopharma, Inc. (STRO): $7.42

-0.28 (-3.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

STRO POWR Grades

  • STRO scores best on the Growth dimension, with a Growth rank ahead of 85.78% of US stocks.
  • STRO's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • STRO's current lowest rank is in the Momentum metric (where it is better than 17.48% of US stocks).

STRO Stock Summary

  • Price to trailing twelve month operating cash flow for STRO is currently 72.23, higher than 94.28% of US stocks with positive operating cash flow.
  • Of note is the ratio of SUTRO BIOPHARMA INC's sales and general administrative expense to its total operating expenses; just 15.73% of US stocks have a lower such ratio.
  • With a price/sales ratio of 6.04, SUTRO BIOPHARMA INC has a higher such ratio than 81.28% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to SUTRO BIOPHARMA INC, a group of peers worth examining would be DTIL, EDIT, FDMT, CYCN, and DCPH.
  • Visit STRO's SEC page to see the company's official filings. To visit the company's web site, go to www.sutrobio.com.

STRO Valuation Summary

  • STRO's EV/EBIT ratio is -2.9; this is 138.16% lower than that of the median Healthcare stock.
  • Over the past 50 months, STRO's price/earnings ratio has gone up 14.1.

Below are key valuation metrics over time for STRO.

Stock Date P/S P/B P/E EV/EBIT
STRO 2022-11-01 7.6 1.9 -3.0 -2.9
STRO 2022-10-31 7.2 1.8 -2.8 -2.8
STRO 2022-10-28 7.1 1.8 -2.8 -2.7
STRO 2022-10-27 6.9 1.7 -2.7 -2.6
STRO 2022-10-26 7.0 1.8 -2.8 -2.7
STRO 2022-10-25 6.8 1.7 -2.7 -2.6

STRO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • STRO has a Quality Grade of D, ranking ahead of 10.85% of graded US stocks.
  • STRO's asset turnover comes in at 0.194 -- ranking 205th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows STRO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.194 1 -0.301
2021-03-31 0.150 1 -0.169
2020-12-31 0.151 1 -0.155
2020-09-30 0.204 1 0.118
2020-06-30 0.212 1 -0.081
2020-03-31 0.246 1 -0.444

STRO Price Target

For more insight on analysts targets of STRO, see our STRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.71 Average Broker Recommendation 1.38 (Strong Buy)

STRO Stock Price Chart Interactive Chart >

Price chart for STRO

STRO Price/Volume Stats

Current price $7.42 52-week high $17.70
Prev. close $7.70 52-week low $3.33
Day low $7.35 Volume 94,000
Day high $7.78 Avg. volume 607,243
50-day MA $6.44 Dividend yield N/A
200-day MA $6.42 Market Cap 426.46M

Sutro Biopharma, Inc. (STRO) Company Bio


Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.


STRO Latest News Stream


Event/Time News Detail
Loading, please wait...

STRO Latest Social Stream


Loading social stream, please wait...

View Full STRO Social Stream

Latest STRO News From Around the Web

Below are the latest news stories about SUTRO BIOPHARMA INC that investors may wish to consider to help them evaluate STRO as an investment opportunity.

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Piper Sandler 34th Annual Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, November 30, 2022Time: 10:30 a.m. ET / 7:30 a.

Yahoo | November 23, 2022

Need To Know: Analysts Are Much More Bullish On Sutro Biopharma, Inc. (NASDAQ:STRO) Revenues

Shareholders in Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be thrilled to learn that the analysts have just delivered a...

Yahoo | November 20, 2022

Analysts Offer Insights on Healthcare Companies: Star Equity Holdings (STRR), Sutro Biopharma (STRO) and Pear Therapeutics (PEAR)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Star Equity Holdings (STRR – Research Report), Sutro Biopharma (STRO – Research Report) and Pear Therapeutics (PEAR – Research Report) with bullish sentiments. Star Equity Holdings (STRR) Maxim Group analyst Tate Sullivan reiterated a Buy rating on Star Equity Holdings yesterday and set a price target of $2.25. The company's shares closed last Monday at $0.90, close to its 52-week low of $0.72. According to TipRanks.

Howard Kim on TipRanks | November 15, 2022

How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%

The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 11, 2022

Sutro Biopharma Third Quarter 2022 Earnings: Misses Expectations

Sutro Biopharma ( NASDAQ:STRO ) Third Quarter 2022 Results Key Financial Results Revenue: US$25.1m (up 195% from 3Q...

Yahoo | November 11, 2022

Read More 'STRO' Stories Here

STRO Price Returns

1-mo 5.85%
3-mo 24.50%
6-mo N/A
1-year -54.14%
3-year -31.17%
5-year N/A
YTD -50.13%
2021 -31.46%
2020 97.36%
2019 21.95%
2018 N/A
2017 N/A

Continue Researching STRO

Here are a few links from around the web to help you further your research on Sutro Biopharma Inc's stock as an investment opportunity:

Sutro Biopharma Inc (STRO) Stock Price | Nasdaq
Sutro Biopharma Inc (STRO) Stock Quote, History and News - Yahoo Finance
Sutro Biopharma Inc (STRO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6566 seconds.